A Case of Autoimmune Pulmonary Alveolar Proteinosis with Suspected Exacerbation after Osimertinib Administration for Lung Cancer

Masafumi Shimoda; Haruyuki Ishii; Yoshiaki Tanaka; Kozo Morimoto; Tamiko Takemura; Teruaki Oka; Kozo Yoshimori; Ken Ohta

doi:10.2169/internalmedicine.0256-22

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

A Case of Autoimmune Pulmonary Alveolar Proteinosis with Suspected Exacerbation after Osimertinib Administration for Lung Cancer

Masafumi Shimoda, Haruyuki Ishii, Yoshiaki Tanaka, Kozo Morimoto, Tamiko Takemura, Teruaki Oka, Kozo Yoshimori, Ken Ohta

著者情報

キーワード: lung cancer, pulmonary alveolar proteinosis, anti-granulocyte/macrophage colony-stimulating factor autoantibody, tyrosine kinase inhibitor, osimertinib

ジャーナルオープンアクセス早期公開

論文ID: 0256-22

DOI https://doi.org/10.2169/internalmedicine.0256-22

この記事には本公開記事があります。

The final version of this article is now available: Vol. 62 (2023), No. 8 pp. 1203-1206

詳細

抄録

A 46-year-old woman with lung cancer who received chemotherapy was admitted to our hospital for lower-lobe bilateral ground-glass opacity (GGO). GGO developed after the lung cancer diagnosis, deteriorated after the initiation of osimertinib, and incompletely decreased after interrupting osimertinib; therefore, flexible bronchoscopy was performed. Transbronchial lung biopsy histology and anti-granulocyte/macrophage colony-stimulating factor autoantibody positivity revealed autoimmune pulmonary alveolar proteinosis (aPAP) that did not require treatment. This rare case of aPAP comorbid with lung cancer suggested that using PAP findings to differentiate from drug-induced lung injury or lymphangitis is difficult and that osimertinib was suspected to exacerbate aPAP.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）